Skip to main content

Day: October 28, 2021

STERIS Declares $0.43 per share Dividend

DUBLIN, IRELAND, Oct. 28, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.43 per share. The dividend is payable December 17, 2021 to shareholders of record at the close of business on November 23, 2021.   STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services.   For more information, visit www.steris.com. Company Contact: Julie Winter, Vice President, Investor Relations and Corporate Communications Julie_Winter@steris.com +1.440.392.7245 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION The release...

Continue reading

NextNav and Spartacus Acquisition Corporation Announce Closing of Business Combination

Combined company renamed NextNav Inc.; Common stock expected to begin trading on Nasdaq under the ticker symbol “NN” on October 29, 2021 Transaction proceeds will accelerate NextNav’s growth strategy to enhance, extend and expand its next generation 3D geolocation technology DULUTH, Ga. and MCLEAN, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) — NextNav, a leader in next generation GPS and 3D geolocation, and Spartacus Acquisition Corporation (NASDAQ: TMTS, TMTSW, and TMTSU) (“Spartacus”), a special purpose acquisition company, today announced that they have completed their previously announced Business Combination (the “Business Combination”), which was approved by Spartacus’ stockholders at its Special Meeting held on October 27, 2021, and closed on October 28, 2021. The combined company will operate as NextNav Inc. (“NextNav”), and its...

Continue reading

NL INDUSTRIES ANNOUNCES QUARTERLY DIVIDEND FOR THE FOURTH QUARTER OF 2021 AT $.06 PER SHARE

Dallas, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE:NL) today announced that its board of directors has declared a quarterly dividend of six cents ($0.06) per share on its common stock payable on December 21, 2021 to shareholders of record at the close of business on December 2, 2021.  NL Industries, Inc. is engaged in the component products (security products and recreational marine components) and chemicals (TiO2) businesses. * * * * * CONTACT: SOURCE: NL Industries, Inc. CONTACT: Janet G. Keckeisen, Investor Relations, 972.233.1700

Continue reading

Fortress Transportation and Infrastructure Investors LLC Reports Third Quarter 2021 Results, Declares Dividend of $0.33 per Common Share

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) (the “Company” or “FTAI”) today reported financial results for the third quarter 2021. The Company’s consolidated comparative financial statements and key performance measures are attached as an exhibit to this press release. Financial Overview(in thousands, except per share data)Selected Financial Results Q3’21Net Cash Provided by Operating Activities $ 43,216  Net Loss Attributable to Shareholders $ (38,871 )Basic and Diluted Loss per Common Share $ (0.44 )   Funds Available for Distribution (“FAD”) (1) $ 39,351  Adjusted EBITDA(1) $ 96,389  _______________________________(1) For definitions and reconciliations of non-GAAP measures, please refer to the exhibit to this press release.   For...

Continue reading

Acutus Medical to Announce Third Quarter 2021 Financial Results

CARLSBAD, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the third quarter of 2021 on Thursday, November 11, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (833) 570-1131 for domestic callers or (914) 987-7078 for international callers, using conference ID: 7373938. The live webinar of the call may be accessed by visiting the Events section of the Acutus investor relations website at ir.acutusmedical.com. A replay...

Continue reading

Hub Group, Inc. Reports Third Quarter 2021 Results

Highlights:        Record quarterly revenue of $1.1 billion, up 16% as compared to last year, driven by strong demand conditions and the benefits of our continued investment in the business Record gross margin of $158 million (14.7% of revenue) driven by favorable pricing and yield improvement, combined with our continued focus on operating efficiency, resulted in third quarter operating income margin of 5.6% of revenue Record net income of $43 million or $1.28 of diluted earnings per share (EPS), which represents year-on-year growth of 73% Generated EBITDA (non-GAAP)1 of $92 million in the quarter Expanded our brokerage and refrigerated transportation offerings through the acquisition of Choptank Transport in October Increased expected full year 2021 diluted earnings per share to $3.90 – $4.00OAK BROOK, Ill., Oct. 28, 2021...

Continue reading

Miromatrix to Report Third Quarter 2021 Financial Results

EDEN PRAIRIE, Minn., Oct. 28, 2021 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the third quarter 2021 after market close on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. Please reference Conference ID: 10161624. To listen to a live webcast, please visit the investor relations section of Miromatrix’s website at: https://miromatrix.gcs-web.com/ About...

Continue reading

Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress

Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of sparsentan in IgA nephropathy for accelerated approval under Subpart H expected in the first quarter of 2022 Based on FDA interactions, accelerated approval submission of sparsentan in FSGS planned for mid-2022, pending additional supportive eGFR data from the ongoing DUPLEX Study Joint collaboration with Vifor Pharma to commercialize sparsentan in Europe; combined IgA nephropathy and FSGS MAA submission for sparsentan in Europe expected mid-2022 Net product sales of $54.2 million for the third quarter of 2021 SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2021 financial...

Continue reading

Lucira Health to Announce Third Quarter 2021 Financial Results

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international callers, using conference ID 8458678. A live and archived webcast of the event can be accessed through the following link ir.lucirahealth.com. About...

Continue reading

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, November 5, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer. Conference call and webcast details:Investors (domestic): 877-407-0792Investors (international): 201-689-8263Conference ID: 13724630   To access a live webcast of the update, please use the following link:   Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1507982&tp_key=2757523ca1   About...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.